Disease relevance of Nocardicin A

• The biosynthetic gene cluster for the nocardicin A producer Nocardia uniformis subsp. tsuyamanensis ATCC 21806 was recently identified [1].
• Induction of cell lysis in Escherichia coli: cooperative effect of nocardicin A and mecillinam [2].
• These properties resulted in a broad spectrum of activity of the combination Nva -Ala(P) plus nocardicin A when used to treat experimental gram-negative bacterial infections [3].
• The interaction of nocardicin A with the penicillin-binding proteins of Bacillus megaterium KM [4].
• Factors influencing the in vitro antimicrobial activity of nocardicin A against Pseudomonas aeruginosa and Proteus mirabilis were investigated [5].

High impact information on Nocardicin A

• Effect of protein synthesis inhibition on the induction of cell lysis in Escherichia coli by mecillinam plus nocardicin A [6].
• The studies of the substrate specificity of the enzyme revealed that UDP-MurNAc-tetrapeptide is a superior substrate, with a Km value of 1 X 10(-4) mol/l. The activity of the LD-carboxypeptidase was inhibited by D-amino acids and the beta-lactam antibiotic nocardicin A [7].
• Certain monocyclic beta-lactams are beta-lactamase substrates: nocardicin A and desthiobenzylpenicillin [8].
• The direct spectrophotometric assay was applied to measure the rate of enzymatic hydrolysis of Nocardicin A [9].
• Chlorocardicin showed low activity against Staphylococcus aureus whereas nocardicin A was inactive [10].

Chemical compound and disease context of Nocardicin A

• The inhibitory activities of representative beta-lactam compounds, such as penicillins G and N, cephalosporins C and G, clavulanic acid, nocardicin A and thienamycin against Escherichia coli KN-126 and Bacillus megaterium KM peptidoglycan transpeptidases were studied [11].

Biological context of Nocardicin A

• The absorption, excretion and tissue distribution of nocardicin A, a new monocyclic beta-lactam antibiotic, were studied in various animals [12].

Anatomical context of Nocardicin A

• The bactericidal activity of nocardicin A against the above 3 organisms, therefore, increased markedly in the presence of fresh serum and polymorphonuclear leukocytes [13].
• It is argued that the effect on phagocyte function is sufficient to contribute materially to the therapeutic effect of nocardicin A [14].
• Human polymorphonuclear leucocytes exposed to low concentrations of the drug in vitro and peritoneal macrophages recovered from mice treated with nocardicin A exhibited an unusually specific form of enhanced activity [14].

Associations of Nocardicin A with other chemical compounds

• The in vitro antimicrobial activity of nocardicin A against clinical isolates of Ps. aeruginosa was about twice that of carbenicillin [13].

Analytical, diagnostic and therapeutic context of Nocardicin A

• Purification of a nocardicin A-sensitive LD-carboxypeptidase from Escherichia coli by affinity chromatography [15].
• The 24-hour urinary recovery rate of nocardicin A after intramuscular injection was 68.5 percent in rabbits and 77.0 percent in dogs, but was low in rats; i.e., 0.7 percent [12].
• The peak serum and tissue levels of nocardicin A after intramuscular to intravenous injection were the highest in the kidneys, followed by the liver, serum, lungs, heart and spleen [12].

References